FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
About | Sample | Privacy

Epix anxiety drug fails in late-stage trial

Shares of Epix Pharmaceuticals slipped after the developer announced that a late stage trial of its experimental long-acting drug for general anxiety disorder failed to achieve a statistically significant response compared to a placebo. PRX-00023 was tested in a Phase III trial that enrolled 310 patients. "Based on these top-line results, we plan to refocus our efforts away from anxiety to evaluate the benefit in depression more closely and assess opportunities for initiating a Phase II clinical trial in depression sooner than originally planned," said Chief Executive Dr. Michael G. Kauffman, in a statement.

- check out the AFX article for more on the trial

More stories about Phase III   pharmaceuticals   Phase II   Drug Trials   CEO   Epix   depression  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 51 + 12?
To combat spam, please solve the math question above.